1. Marcelin G, Clément K. The multifaceted progenitor fates in healthy or unhealthy adipose tissue during obesity. Rev Endocr Metab Disord 2021;22:1111–1119.

2. Yárnoz-Esquiroz P, Olazarán L, Aguas-Ayesa M, et al. ‘Obesities’: position statement on a complex disease entity with multifaceted drivers. Eur J Clin Invest 2022;52:e13811.

3. Wright SM, Aronne LJ. Causes of obesity. Abdom Imaging 2012;37:730–732.

4. Rolls BJ. The supersizing of America: portion size and the obesity epidemic. Nutr Today 2003;38:42–53.

5. Madamsetty VS, Mohammadinejad R, Uzieliene I, et al. Dexamethasone: insights into pharmacological aspects, therapeutic mechanisms, and delivery systems. ACS Biomater Sci Eng 2022;8:1763–1790.

6. Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018;77:644–649.

7. Box CD, Cronin O, Hauser B. The impact of high dose glucocorticoids on bone health and fracture risk in systemic vasculitides. Front Endocrinol (Lausanne) 2022;13:806361.

8. Teng D, Pang QF, Yan WJ, Zhao Xin W, Xu CY. The harmful effect of prolonged high-dose methylprednisolone in acute lung injury. Int Immunopharmacol 2013;15:223–226.

9. Ferraù F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 2015;173:M133–M157.

10. Peacey SR, Wright D, Aye M, Moisey R. Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism. Clin Endocrinol (Oxf) 2012;77:94–98.

11. Ji L, Gao D, Hao Y, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal. Rheumatology (Oxford) 2022;62:181–189.

12. Kola B, Christ-Crain M, Lolli F, et al. Changes in adenosine 5’-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing’s syndrome. J Clin Endocrinol Metab 2008;93:4969–4973.

13. Poggioli R, Ueta CB, Drigo RA, Castillo M, Fonseca TL, Bianco AC. Dexamethasone reduces energy expenditure and increases susceptibility to diet-induced obesity in mice. Obesity (Silver Spring) 2013;21:E415–E420.

14. Liu H, He B, Hu W, et al. Prenatal dexamethasone exposure induces nonalcoholic fatty liver disease in male rat offspring via the miR-122/YY1/ACE2-MAS1 pathway. Biochem Pharmacol 2021;185:114420.

15. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20.

16. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005;115:1139–1142.

17. Wu T, Yang L, Jiang J, et al. Chronic glucocorticoid treatment induced circadian clock disorder leads to lipid metabolism and gut microbiota alterations in rats. Life Sci 2018;192:173–182.

18. Wu T, Jiang J, Yang L, et al. Timing of glucocorticoid administration determines severity of lipid metabolism and behavioral effects in rats. Chronobiol Int 2017;34:78–92.

19. Wan J, Shan Y, Song X, et al. Adipocyte-derived Periostin mediates glucocorticoid-induced hepatosteatosis in mice. Mol Metab 2020;31:24–35.

20. Chen M, Bai M, Yi Y, et al. Upregulation of hepatic CD36 via glucocorticoid receptor activation contributes to dexamethasone- induced liver lipid metabolism disorder in mice. Toxicol Lett 2022;363:1–10.

21. Jiao T, Yao X, Zhao Y, et al. Dexamethasone-induced liver enlargement is related to PXR/YAP activation and lipid accumulation but not hepatocyte proliferation. Drug Metab Dispos 2020;48:830–839.

22. Feng B, He Q, Xu H. FOXO1-dependent up-regulation of MAP kinase phosphatase 3 (MKP-3) mediates glucocorticoid-induced hepatic lipid accumulation in mice. Mol Cell Endocrinol 2014;393:46–55.

23. Hua H, Dai M, Luo Y, et al. Basal PPARα inhibits bile acid metabolism adaptation in chronic cholestatic model induced by α-naphthylisothiocyanate. Toxicol Lett 2019;300:31–39.

24. Dai M, Yang J, Xie M, et al. Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate. Br J Pharmacol 2017;174:3000–3017.

25. Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 2016;127:296–302quiz 370.

26. Li HY, Dahir KM, Blevins LS Jr. Treatment of adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a clinical practice audit. Endocr Pract 2003;9:347–352.

27. Al-Harbi NO, Imam F, Al-Harbi MM, et al. Dexamethasone attenuates LPS-induced acute lung injury through inhibition of NF-κB, COX-2, and pro-inflammatory mediators. Immunol Invest 2016;45:349–369.

28. Pyrillou K, Chairakaki AD, Tamvakopoulos C, Andreakos E. Dexamethasone induces ω3-derived immunoresolvents driving resolution of allergic airway inflammation. J Allergy Clin Immunol 2018;142:691–695e4.

29. Abad V, Chrousos GP, Reynolds JC, et al. Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat. J Bone Miner Res 2001;16:1879–1885.

30. Tack LJ, Tatsi C, Stratakis CA, Lodish MB. Effects of Glucocorticoids on bone: what we can learn from pediatric endogenous Cushing’s syndrome. Horm Metab Res 2016;48:764–770.

31. Ghaben AL, Scherer PE. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol 2019;20:242–258.

32. Camargo FD, Gokhale S, Johnnidis JB, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007;17:2054–2060.

33. Li H, Wu BK, Kanchwala M, et al. YAP/TAZ drives cell proliferation and tumour growth via a polyamine-eIF5A hypusination-LSD1 axis. Nat Cell Biol 2022;24:373–383.

34. Zhang R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. Open Biol 2016;6:150272.

35. Sztolsztener K, Harasim-Symbor E, Chabowski A, Konstan-tynowicz-Nowicka K. The influence of dexamethasone on hepatic fatty acids metabolism and transport in human steatotic HepG2 cell line exposed to palmitate. Biochem Biophys Res Commun 2021;585:132–138.

36. Chimin P, Farias Tda S, Torres-Leal FL, et al. Chronic glucocorticoid treatment enhances lipogenic activity in visceral adipocytes of male Wistar rats. Acta Physiol (Oxf) 2014;211:409–420.

37. Liu H, Liu D, Ji M, et al. Inflammation-targeted sialic acid- dexamethasone conjugates for reducing the side effects of glucocorticoids. Int J Pharm 2022;622:121900.

38. Sinha P, Verma B, Ganesh S. Dexamethasone-induced activation of heat shock response ameliorates seizure susceptibility and neuroinflammation in mouse models of Lafora disease. Exp Neurol 2021;340:113656.

39. Guzzo EFM, Lima KR, Vargas CR, Coitinho AS. Effect of dexamethasone on seizures and inflammatory profile induced by Kindling Seizure Model. J Neuroimmunol 2018;325:92–98.